title: [Systemic Adamantiades-Behçet's disease: adverse effects of an otherwise successful therapy with interferon-α-2a].
abstract: BACKGROUND
  Adamantiades-Behçet's disease is an immune-mediated vasculitis with relapsing course. It is characterised by the classic clinical trias of oral aphthous ulcers, genital ulcers and uveitis.
  
  
  METHODS
  A 37-year-old woman suffered from systemic Adamantiades-Behçet disease with recurrent uveitis, oral ulcers, genital ulcers, arthralgia, erythema nodosum and folliculitis.
  
  
  RESULTS
  Longterm interferon-α-2a (IFNα-2a) led to reduction of the clinical manifestations except for occasional occurrence of oral ulcers. One year after initiation of treatment however, the patient developed symptomatic hyperprolactinemia of unknown etiology.
  
  
  CONCLUSIONS
  Even in otherwise successful treatment with IFNα-2a possible side effects and complications of treatment can affect the course. Mastodynia and hyperprolactinemia have not yet been described as potential side effects of IFNα-2a.
authors.affiliation: Klinik für Dermatologie, Venerologie und Allergologie, Immunologisches Zentrum, Städtisches Klinikum Dessau.
authors.forename: Ioannis
authors.initials: I
authors.lastname: Karagiannidis
authors.affiliation: Klinik für Dermatologie, Venerologie und Allergologie, Immunologisches Zentrum, Städtisches Klinikum Dessau.
authors.forename: Christos C
authors.initials: CC
authors.lastname: Zouboulis
mesh_terms: D000328:Adult; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use; D001528:Behcet Syndrome / Q000175:diagnosis* / Q000188:drug therapy*; D005260:Female; D006801:Humans; D006966:Hyperprolactinemia / Q000139:chemically induced* / Q000175:diagnosis / Q000517:prevention & control; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use*; D059373:Mastodynia / Q000139:chemically induced* / Q000175:diagnosis / Q000517:prevention & control; D019226:Oral Ulcer / Q000139:chemically induced* / Q000175:diagnosis / Q000517:prevention & control; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins